Developments in clinical practice treating systemic lupus erythematosus—A single-centre retrospective longitudinal study in Japan
- 22 January 2026
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (4) , 566-573
Abstract
Objectives: To assess treatment patterns for systemic lupus erythematosus from 2012 to 2024 and evaluate corresponding changes in serological activity and relapse rates. Methods: We retrospectively reviewed medical records of 1705 patients with systemic lupus erythematosus treated at a single centre between 2012 and 2024. Temporal trends in therapeutic approaches, glucocorticoid (GC) use, and clinical outcomes were analysed. Results: Use of GC monotherapy declined from 58.3% in 2012 to 22.4% in 2024. Combination therapies (GC and hydroxychloroquine, with or without immunosuppressants) increased from 1.0% in 2015 to 41.6% in 2024, while biologics use rose from 0.9% in 2018 to 12.5% in 2024. Quadruple therapy (GC, hydroxychloroquine, immunosuppressants, and biologics) also expanded from 0.4% in 2018 to 6.2% in 2024. The mean GC dose decreased from 7.7 mg/day in 2012 to 4.6 mg/day in 2024, and the median dose, stable at 5 mg/day for many years, declined to 4.6 mg in 2023 and 4.2 mg in 2024. The proportion of patients with elevated serological activity steadily decreased. Flare rates peaked at 8.1% in 2016 but stabilised at ~4% after 2020. Conclusions: These findings suggest that improved disease control can increasingly be achieved in real-world practice while reducing long-term GC dependence.Keywords
This publication has 19 references indexed in Scilit:
- Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance ClaimsModern Rheumatology, 2025
- Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational StudyAdvances in Therapy, 2022
- Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort StudyArthritis Care & Research, 2021
- Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugsRheumatology, 2020
- Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database studyJournal of Medical Economics, 2020
- Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United StatesJournal of Medical Economics, 2019
- Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of TreatmentArthritis Care & Research, 2019
- Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasiaScientific Reports, 2017
- Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE studyModern Rheumatology, 2016
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997